Ann: Prima Biomed granted Orphan Drug designation, page-7

re: Ann: Prima Biomed granted Orphan Drug des... Expected or not...this is great news, and has added value to the stock, regardless of the SP movement.

Key points
? Prima BioMed granted Orphan Medicinal Product Designation for CVac?
ovarian cancer therapy vaccine in Europe
? Orphan Product designation gives Prima exclusive rights to CVac? for a 10
year period post commercial approval
? Orphan Product designation also provides the provision of tax reductions
in development period for CVac?
? The designation is a significant step in Prima?s goal of commercialising
CVac? into the multi-billion global pharmacy oncology market
? Orphan Product designation provides incentives for companies pursuing
cures and treatments for rare diseases, such as ovarian cancer
? Incentives include; fast tracking, research support, protocol assistance and
exemptions in certain regulatory fees

IMHO...its not so much that thigs are "factored in", but more that the price is quite obviously being held back, creating the illusion of things being "factored in".

I wish I knew what these manipulators know.......